

## Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D.



---

Biohaven Ltd., a global clinical-stage biopharmaceutical company announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.

Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. Kozauer led the division responsible for the regulation of all Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biological Licensing Applications (BLAs) for drugs being developed and/or approved for the treatment of neuroimmunologic conditions, epilepsies, migraine, stroke, traumatic brain injury, inner ear disorders, and other products.

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "It is a great honor to welcome Dr. Kozauer to the Biohaven team. Dr. Kozauer is a true clinician-researcher who has supervised and reviewed the approval of over 15 marketed drugs during his tenure at the FDA. His knowledge and expertise in the regulatory process, as well as his deep experience in diseases including neuroimmunology and epilepsy, will only strengthen Biohaven's ability to efficiently advance our robust pipeline of compounds and deliver novel treatments in high unmet need areas in neuroscience for patients and their families. Dr. Kozauer has already positively impacted patient care during his time at the FDA and we are excited to have him on our team to help us innovate new therapies."

Prior to joining the FDA, Dr. Kozauer worked in academia at the Johns Hopkins Memory Center at the Copper Ridge Institute where he oversaw clinical care of patients with Alzheimer's disease and other dementias, and in private practice focusing on complex neuropsychiatric conditions. Dr. Kozauer completed his residency and fellowship training at Georgetown University Medical Center and Johns Hopkins, respectively, and received his M.D. from Rutgers-New Jersey Medical School.

Dr. Kozauer stated, "I am energized by the opportunity to work with such an experienced, dynamic, and patient-focused group of individuals pursuing groundbreaking science to develop a broad range of therapies for serious diseases with unmet medical needs. The team at Biohaven has demonstrated its ability to bring innovative medicines to patients and has an exciting portfolio including immune modulating agents, ion channel activators, myostatin targeting agent and other investigational drugs targeting ultra-rare diseases."

**Source:** [Biohaven](#)

Published on : Mon, 17 Apr 2023